Q2 oncology calendar set

The Food and Drug Administration’s next cancer decisions are clustering in late spring, with June 2, 2026 set for Datroway in metastatic triple-negative breast cancer and several other oncology filings close behind. (targetedonc.com) (daiichisankyo.us) Cancer drug reviews often turn on whether a medicine helps patients live longer or keeps the disease from growing longer than standard treatment. In this case, Daiichi Sankyo and AstraZeneca said Datroway won Priority Review for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for programmed death receptor-1 or programmed death ligand-1 inhibitor therapy, with a June 2 action date. (fda.gov) (daiichisankyo.us) The companies said the filing rests on the phase 3 TROPION-Breast02 trial, where Datroway improved median overall survival by 5.0 months and cut the risk of progression or death by 43% against investigator’s-choice chemotherapy. They also reported an objective response rate of 62.5% versus 29.3% and a median duration of response of 12.3 months versus 7.1 months. (daiichisankyo.us) Datroway is already on the market in the United States for two other settings: hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer since January 17, 2025, and epidermal growth factor receptor-mutated non-small cell lung cancer since June 23, 2025. That gives doctors and regulators an existing safety file as they weigh a broader first-line use in a harder-to-treat breast cancer subtype. (fda.gov 1) (fda.gov 2) The label already warns that Datroway can cause eye problems, mouth sores, lung inflammation and embryo-fetal harm. Food and Drug Administration review documents also tie higher exposure to higher rates of serious adverse reactions, dose interruptions and grade 3 or worse toxic effects. (accessdata.fda.gov 1) (accessdata.fda.gov 2) The blood-cancer side of the calendar shifted on April 1, 2026, when Orca Bio said the Food and Drug Administration pushed its Orca-T decision from April 6 to July 6 after the company submitted updated chemistry, manufacturing and controls information. Orca Bio said the agency did not ask for new clinical data. (orcabio.com) Orca-T is a donor-cell transplant product designed to rebuild a patient’s blood and immune system with a more tightly selected mix of cells. Orca Bio said its biologics license application seeks approval in hematologic malignancies including acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndromes, and that the product would be the first allogeneic T-cell immunotherapy in that setting if cleared. (fda.gov) (orcabio.com) The company’s phase 3 Precision-T study compared Orca-T with conventional donor stem-cell transplant and reported a 78% rate of survival free from moderate-to-severe chronic graft-versus-host disease versus 38.4% with standard transplant. Orca Bio also said the difference was driven by fewer cases of chronic graft-versus-host disease and fewer deaths. (orcabio.com) The quarter’s calendar is useful partly because it shows how different the regulatory questions are from one cancer filing to the next. One June decision asks whether an antibody-drug conjugate should move earlier in breast cancer care, while the delayed Orca-T review asks whether a complex cell therapy can clear the agency’s manufacturing and product-control bar as well as its clinical one. (targetedonc.com) (orcabio.com) By early July, the calendar should answer at least one of those questions and leave a paper trail for the rest: what the Food and Drug Administration was willing to accept on survival, side effects and manufacturing in cancer care in 2026. (daiichisankyo.us) (orcabio.com)